In short
Clinical trials are investigating VGA039 in people with von Willebrand Disease. The studies are looking at whether VGA039 can help prevent bleeding, with a focus on safety and efficacy in adolescent and adult patients. The main trial is a Phase 3 study in people who have not previously used prophylactic von Willebrand Factor-containing concentrates.
Key points
- Clinical trials are investigating VGA039 in people with von Willebrand Disease, a bleeding disorder. The main study is a Phase 3 trial in adolescent and adult patients. It is looking at whether VGA039 can help prevent bleeding in people who have not previously used von Willebrand Factor-containing concentrates on a preventive basis. The key outcome is the annualized bleeding rate, which shows how often bleeding happens over one year. The trial is authorised and plans to enroll 54 participants.
Clinical trials overview
One authorised Phase 3 interventional study is testing VGA039 in people with von Willebrand Disease.
The study is designed to assess the effect of subcutaneous VGA039 prophylaxis, which means preventive treatment given under the skin, on bleeding events.
Who the study is for
The trial is for adolescent and adult patients with von Willebrand Disease.
It focuses on people who previously did not receive von Willebrand Factor-containing concentrates on a prophylactic basis, meaning they did not use these products regularly to prevent bleeding.
What the trial measures
The main endpoint is annualized bleeding rate (ABR).
ABR is a way to measure how many bleeding events happen over one year, so researchers can see whether the treatment helps reduce bleeding.
Trial status and size
The study status is Authorised, which means it has been allowed to start.
The planned enrollment is 54 participants.
What this means for patients
This trial is part of clinical research to learn whether VGA039 can help prevent bleeding in a specific group of people with von Willebrand Disease.
Because it is a Phase 3 study, the researchers are studying the treatment in a larger group to better understand its benefit in real patients.